204
Participants
Start Date
February 1, 2020
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2030
Allogeneic Stem Cell Transplant
The allogeneic stem cell transplant involves transferring the stem cells from a healthy person (donor) to the participant via infusion.
CliniMACS TCR α/β Reagent Kit and CliniMACS CD19
The CliniMACS™system can be used to selectively enrich or reduce specific cell populations based on the magnetic cell selection (MACS) technology developed by Miltenyi Biotec. Cell mixtures can be separated in a magnetic field using one or more immunomagnetic- labeled antibodies specific for the cell types of interest (e.g.TCR αβ+ T cells and CD19+ B cells from HPC(A) products).
RECRUITING
Lucile Packard Children's Hospital, Palo Alto
Alice Bertaina
OTHER